Please login to the form below

Not currently logged in
Email:
Password:

flibanserin

This page shows the latest flibanserin news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

for 'female Viagra' after the FDA backed Addyi (flibanserin) for hypoactive sexual desire disorder in women. ... South Korea. evolocumab. Repatha. hypercholesterolaemia. PCSK9 inhibitor. Amgen. EU. flibanserin. Addyi.

Latest news

  • Valeant swoops on Sprout to claim female sexual disorder drug Valeant swoops on Sprout to claim female sexual disorder drug

    The agreement looks set to accelerate the roll-out of Addyi outside the US, with Valeant pledging to "leverage its global scale to register flibanserin internationally". ... Expect future news to include stories of women who are harmed needlessly by

  • FDA approves first female sexual disorder drug FDA approves first female sexual disorder drug

    The 'little pink pill' - which contains the non-hormonal drug flibanserin - finally got the go-ahead from the FDA at the third attempt, ending a marathon development effort marked by rejections

  • FDA panel backs Sprout Pharma's 'female Viagra' FDA panel backs Sprout Pharma's 'female Viagra'

    The panel voted by 18 to 6 that the drug - called flibanserin - should be approved to treat hypoactive sexual desire disorder (HSDD) in pre-menopausal women, opening the door for a ... If given the nod by the FDA, flibanserin would become the first ever

  • Trials show effectiveness for HSDD

    Flibanserin 100mg taken once daily at bedtime significantly increased the number of satisfying sexual events (SSEs) and sexual desire while reducing the distress associated with HSDD, according to data. ... Flibanserin is a novel, non-hormonal compound,

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    This month the deal was the purchase of Sprout Pharmaceuticals for $1bn cash in two instalments of $500m bringing the recently approved product Addyi (flibanserin) which is used for hypoactive sexual

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics